31 January 2020
: Case report
Paraneoplastic Leukemoid Reaction in Gastroesophageal Junction Adenocarcinoma: A Case Report
Challenging differential diagnosis, Rare disease
Kevin Wei-Lun Chang1EF*, Lai Lai Kwok2EF, Manish K. Rana3EF, Sapna Patel4E, Thomas Birris5EDOI: 10.12659/AJCR.919596
Am J Case Rep 2020; 21:e919596
Abstract
BACKGROUND: The presence of leukocytosis associated with non-hematological malignancy after ruling out other causes is defined as paraneoplastic leukemoid reaction (PLR). PLR is a rare manifestation of various solid tumors. It is associated with poor prognosis unless receiving effective antineoplastic treatments.
CASE REPORT: A 72-year-old female was referred to a hematologist/oncologist for the evaluation of leukocytosis with neutrophilia. Initial workup was unremarkable; however, she had progressively worsening leukocytosis with neutrophilia, associated with severe anemia and dysphagia. Computed tomography (CT) scan revealed wall thickening at the gastroesophageal junction (GEJ) and multiple hypodensities of the liver. Esophagogastroduodenoscopy (EGD) confirmed the diagnosis of GEJ tumor and biopsy returned as adenocarcinoma with human epidermal growth factor receptor 2 (HER2) overexpression. Leukocytosis resolved after the first round of chemotherapy and the patient remains progression-free with the addition of trastuzumab to her chemotherapy regimen.
CONCLUSIONS: We report a rare case of PLR caused by GEJ adenocarcinoma. This is the first case of PLR in a patient with metastatic GEJ adenocarcinoma with HER2 overexpression in the Caucasian population. It is important to workup leukocytosis promptly, to keep malignancy in the differential diagnosis and to seek early hematology/oncology consultation.
Keywords: Esophagogastric Junction, Genes, erbB-2, Leukemoid Reaction, Neoplasms, Paraneoplastic Syndromes, Adenocarcinoma, Aged, Drug Therapy, Combination, Endoscopy, Digestive System, Esophageal Neoplasms, Liver, Receptor, erbB-2, Trastuzumab
SARS-CoV-2/COVID-19
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
02 April 2023 : Case report
Am J Case Rep 2023; 24:e938732
31 March 2023 : Case report
Am J Case Rep 2023; 24:e938761
In Press
31 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938131
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939200
30 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939365
28 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939387
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347